Abstract
As indicated in the previous chapter, molecular therapeutic approaches to cancer are often geared at interfering with signaling pathways that govern cell fate or proliferation. These strategies target kinases, the signal transducers in the cell. This approach remains challenging because kinases are evolutionarily and therefore structurally related and thus kinase inhibitors (KIs) often lack the required specificity, which may lead to toxic side effects. This chapter illustrates the power of the wrapping concept in engineering safer KIs, thus unraveling a rational approach to fulfill this therapeutic imperative. The focus of this chapter is the redesign of the anticancer drug imatinib (Gleevec) used to treat chronic myeloid leukemia, where its primary target is the chimeric Bcr-Abl kinase, as well as certain solid tumors based on its impact on the C-Kit kinase. Imatinib also has potentially cardiotoxic effects traceable to its impact on the Abl kinase in off-target cells. This chapter describes a wrapping modification of imatinib purposely designed to prevent inhibitory impact against Abl (and Bcr-Abl), to refocus the impact toward C-Kit and to promote inhibition of an additional target, JNK, required to reinforce the prevention of cardiotoxicity and recognized as a target of significant therapeutic interest in its own right. The molecular blueprint for target discrimination, described in Chaps. 4 and 6, is now validated through assays that span a vast testing ground, from in silico assessment and test tube probes to animal models. The findings surveyed in this chapter identify the wrapping-based re-engineered imatinib as an agent to treat gastrointestinal stromal tumors and possibly ovarian cancer (via its differential anti-JNK activity) with reduced side effects, thereby illustrating the therapeutic impact of the wrapping technology.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Dancey J, Sausville EA (2003) Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2:296–313
Levitski A, Gazit A (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267:1782–1788
Tibes R, Trent J, Kurzrock R (2005) Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu Rev Pharm Tox 45:357–384
Gibbs J, Oliff A (1994) Pharmaceutical research in molecular oncology. Cell 79:193–198
Donato NJ, Talpaz M (2000) Clinical use of tyrosine kinase inhibitors: therapy for chronic myelogenous leukemia and other cancers. Clin Cancer Res 6:2965–2966
Fabian MA, Biggs WH, Treiber DK et al (2005) A small molecule kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329–336
Gambacorti-Passerini C, le Coutre P, Mologni L et al (1997) Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL + leukemic cells and induces apoptosis. Blood Cells Mol Dis 23:380–394
Schindler T, Bornmann W, Pellicena P et al (2000) Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289:1938–1942
Attoub S, Rivat C, Rodrigues S et al (2002) The c-kit tyrosine kinase inhibitor STI-571 for colorectal cancer therapy. Cancer Res 62:4879–4883
DeMatteo RP (2002) The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol 9:831–839
Skene RJ, Kraus ML, Scheibe DN et al (2004) Structural basis for autoinhibition and STI-571 inhibition of c-kit tyrosine kinase. J Biol Chem 279:31655–31663
Tuveson DA, Willis NA, Jacks T et al (2001) STI571 inactivation of the gastrointestinal stromal tumor c-kit oncoprotein: biological and clinical implications. Oncogene 20:5054–5058
Chen JP, Zhang X, Fernández A (2007) Molecular basis for specificity in the druggable kinome: sequence-based analysis. Bioinformatics 23:563–572
Fernández A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, Trent J, Lin Y, Han HD, Mangala LS, Bankson JA, Gelovani J, Samarel A, Bornmann W, Sood AK, Lopez-Berestein G (2007) An anticancer c-kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest 117:4044–4054
Kerkela R, Grazette L, Yacobi R et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908–916
Druker BJ (2004) Molecularly targeted therapy: have the floodgates opened? Oncologist 9:357–360
Vivas-Mejia P, Benito JM, Fernández A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, Sanguino A, Peng Z, Sood AK, Lopez-Berestein G (2010) c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res 16:184–194
Fernández A, Scheraga HA (2003) Insufficiently dehydrated hydrogen bonds as determinants of protein interactions. Proc Natl Acad Sci USA 100:113–118
Barker S, Kassel D, Weigl D et al (1995) Characterization of pp60c-src tyrosine kinase activities using a continuous assay: autoactivation of the enzyme is an intermolecular autophosphorylation process. Biochemistry 34:14843–14851
Songyang Z, Carraway KL, Eck M et al (1995) Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373:536–539
Clarkson B, Strife A, Wisniewski D, Lambek CL, Liu C (2003) Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategy. Leukemia 17:1211–1262
Baines CP, Molkentin JD (2005) Stress signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol 38:47–62
Prenen H, Deroose C, Vermaelen P, Sciot R, Debiec-Rychter M (2006) Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to Imatinib by small animal positron emission tomography. Anticancer Res 26:1247–1252
Scheuermann-Freestone M, Simon Freestone N, Langenickel T et al (2001) A new model of congestive heart failure in the mouse due to chronic volume overload. Eur J Heart Fail 3:535–543
Theoharides T (2008) Mast cells and pancreatic cancer. N Engl J Med 358:1860–1861
Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, Liu Y, Yuan Y, Unkeless J, Xiong H, Feng ZH (2008) SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 112:1269–1279
Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen SH (2011) Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hemat 77:12–19
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Fernández Stigliano, A. (2015). Wrapping-Based Re-engineering of an Anticancer Drug to Make it Safer. In: Biomolecular Interfaces. Springer, Cham. https://doi.org/10.1007/978-3-319-16850-0_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-16850-0_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-16849-4
Online ISBN: 978-3-319-16850-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)